FTSE 100 news / Companies and sectors / GSK / Gates funding for GSK tuberculosis research extended

Gates funding for GSK tuberculosis research extended

+5.4 positive

GSK received extended Gates funding for TB drug research.

3 headlines from 3 outlets, from 1 October 2026 to 5 October 2026. The story's tone is the average of its headlines' own scores.

How each outlet covered it

Average tone of each outlet's headlines in this story. One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Outlet	Headlines	Tone
Simply Wall Street	1	+6.7
Kalkine Media	1	+6.7
Pulse 2.0	1	+3.0

Day by day

Monday 5 October 2026 1 headline

AN2 Therapeutics secured extended Gates Foundation funding for the GSK tuberculosis collaboration.

+3.0 AN2 Therapeutics Secures Extended Gates Foundation Funding For GSK Tuberculosis Collaboration Pulse 2.0
Extended funding for a TB collaboration involving GSK; modest positive, partner-focused.

Thursday 1 October 2026 2 headlines

GSK received extended Gates funding for TB drug research.

+6.7 GSK (LSE:GSK) Gets Extended Gates Funding For Tuberculosis Drug Research Simply Wall Street
Extended Gates funding for tuberculosis drug research.
+6.7 GSK (LSE:GSK) Expands TB Research as Gates Funding Continues Kalkine Media
Continued Gates funding supports GSK's TB research expansion.

GSK: all news analysis · Sector · FTSE 100 news